SCM
CLDI icon

Shaolin Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

Shaolin Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-104
Closed -$2.07M – 644
2023
Q1 		$2.05M Hold
104
– – 0.06% 236
2022
Q4 		$2.03M Hold
104
– – 0.06% 294
2022
Q3 		$1.97M Sell
104
-625
-86% -$12M 0.05% 358
2022
Q2 		$13.9M Buy
729
+119
+20% +$2.27M 0.33% 53
2022
Q1 		$11.6M Buy
610
+519
+570% +$9.81M 0.29% 69
2021
Q4 		$1.72M Buy
+91
New +$1.72M 0.04% 411

Other funds holding CLDI

MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SAMC
Spectrum Asset Management (California) Newport Beach, California $360M AUM 19.03% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $394M AUM 20.27% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $608M AUM 25.3% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Shaolin Capital Management's CLDI Position: Q2 2023 in Review

Shaolin Capital Management sold out of Calidi Biotherapeutics (CLDI) in Q2 2023, closing a stake of 104 shares — an estimated $2.07M sold.

Shaolin Capital Management first reported a position in CLDI in Q4 2021 and held it in 6 quarters. The position peaked at $13.9M in Q2 2022. 24 funds tracked by Wall St. Rank hold CLDI as of Q2 2023.

  • Shaolin Capital Management reported no remaining Calidi Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Shaolin Capital Management sold 104 Calidi Biotherapeutics shares in Q2 2023, an estimated $2.07M.
  • Shaolin Capital Management first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 6 quarters.
  • Shaolin Capital Management's Calidi Biotherapeutics position peaked at $13.9M in Q2 2022.
  • 24 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2023.

Based on Shaolin Capital Management's 13F filing for Q2 2023, filed 15 Aug 2023.